Mesoblast Ltd.

Mesoblast Ltd. is a global regenerative‑medicine biopharma advancing mesenchymal‑cell therapies—Remestemcel‑L (Phase III for inflammatory and cardiac disorders) and MPC‑300‑IV—supported by strategic partners such as Tasly, JCR, and Grünenthal.

Headquarters: Australia (AUS)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Hospitals and Health Care
Industry: Medical Practices

Employees: 81
HQ: Melbourne

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
MSB	Mesoblast Ltd. Cap: 3.5B	EQUITY	ASX	AUD	AU000000MSB8	Active	📈